{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:14:26Z","timestamp":1794964466965,"version":"4.9.1"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1038\/s41581-026-01078-w","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:16:31Z","timestamp":1778156191000},"page":"855-868","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Epidemiology of cardiovascular\u2013kidney\u2013metabolic syndrome"],"prefix":"10.1038","volume":"22","author":[{"given":"Lucas A.","family":"Mavromatis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4430-6023","authenticated-orcid":false,"given":"Morgan E.","family":"Grams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"1078_CR1","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1681\/ASN.0000000658","volume":"36","author":"Z Xie","year":"2025","unstructured":"Xie, Z. et al. Global burden of the key components of cardiovascular-kidney-metabolic syndrome. J. Am. Soc. Nephrol. 36, 1572\u20131584 (2025).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1078_CR2","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele, C. E. et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation 148, 1606\u20131635 (2023).","journal-title":"Circulation"},{"key":"1078_CR3","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele, C. E. et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation 148, 1636\u20131664 (2023).","journal-title":"Circulation"},{"key":"1078_CR4","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1001\/jama.2024.6892","volume":"331","author":"R Aggarwal","year":"2024","unstructured":"Aggarwal, R., Ostrominski, J. W. & Vaduganathan, M. Prevalence of cardiovascular-kidney-metabolic syndrome stages in US adults, 2011\u20132020. JAMA\u00a0331, 1858\u20131860 (2024).","journal-title":"JAMA"},{"key":"1078_CR5","volume":"10","author":"SE Claudel","year":"2025","unstructured":"Claudel, S. E., Schmidt, I. M., Waikar, S. S. & Verma, A. Cumulative incidence of mortality associated with cardiovascular-kidney-metabolic syndrome. J. Am. Soc. Nephrology 10, 1681 (2025).","journal-title":"J. Am. Soc. Nephrology"},{"key":"1078_CR6","doi-asserted-by":"publisher","first-page":"e2445309","DOI":"10.1001\/jamanetworkopen.2024.45309","volume":"7","author":"R Zhu","year":"2024","unstructured":"Zhu, R. et al. Prevalence of cardiovascular-kidney-metabolic syndrome stages by social determinants of health. JAMA Netw. Open. 7, e2445309\u2013e2445309 (2024).","journal-title":"JAMA Netw. Open."},{"key":"1078_CR7","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.jacc.2024.03.368","volume":"83","author":"AMK Minhas","year":"2024","unstructured":"Minhas, A. M. K. et al. Prevalence of the cardiovascular-kidney-metabolic syndrome in the United States. J. Am. Coll. Cardiol. 83, 1824\u20131826 (2024).","journal-title":"J. Am. Coll. Cardiol"},{"key":"1078_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101754","volume":"4","author":"R Chang","year":"2025","unstructured":"Chang, R., Parekh, T., Hagan, K. K., Javed, Z. & Ostrominski, J. W. State-level prevalence of cardiovascular-kidney-metabolic syndrome stages in the United States, 2011 to 2023. JACC Adv. 4, 101754 (2025).","journal-title":"JACC Adv."},{"key":"1078_CR9","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1111\/dom.13303","volume":"20","author":"SV Arnold","year":"2018","unstructured":"Arnold, S. V. et al. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Diabetes Obes. Metab. 20, 2000\u20132003 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"1078_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jacasi.2024.12.003","volume":"5","author":"H Zhang","year":"2025","unstructured":"Zhang, H. et al. Prevalence of cardiovascular-kidney-metabolic syndrome stages among middle-aged and older adults in China. JACC Asia 5, 393\u2013395 (2025).","journal-title":"JACC Asia"},{"key":"1078_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2025.05.030","volume":"86","author":"D He","year":"2025","unstructured":"He, D. et al. Rising prevalence of cardiovascular-kidney-metabolic syndrome in China, 2010-2019. J. Am. Coll. Cardiol. 86, 213\u2013216 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1078_CR12","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2025005","volume":"47","author":"SB Hong","year":"2025","unstructured":"Hong, S. B. et al. Prevalence of cardiovascular-kidney-metabolic syndrome in Korea: Korea National Health and Nutrition Examination Survey 2011\u20132021. Epidemiol. Health 47, e2025005 (2025).","journal-title":"Epidemiol. Health"},{"key":"1078_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111926","volume":"218","author":"V Trimarco","year":"2024","unstructured":"Trimarco, V. et al. Increased prevalence of cardiovascular-kidney-metabolic syndrome during COVID-19: a propensity score-matched study. Diabetes Res. Clin. Pract. 218, 111926 (2024).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1078_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100325","volume":"13","author":"Y-P Zhang","year":"2025","unstructured":"Zhang, Y.-P. et al. Cardiovascular-kidney-metabolic health, genetic susceptibility, and the risk of dementia: a prospective cohort study. J. Prev. Alzheimers Dis. 13, 100325\u00a0(2025).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1078_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1161\/ATVBAHA.124.321629","volume":"45","author":"H Ji","year":"2025","unstructured":"Ji, H. et al. Sex differences in cardiovascular-kidney-metabolic syndrome: 30-year US trends and mortality risks \u2014 brief report. Arterioscler. Thromb. Vasc. Biol. 45, 157\u2013161 (2025).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1078_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"Saeedi, P. et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res. Clin. Pract. 157, 107843 (2019).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1078_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S2213-8587(19)30026-9","volume":"7","author":"LM Jaacks","year":"2019","unstructured":"Jaacks, L. M. et al. The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol. 7, 231\u2013240 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1078_CR18","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0140-6736(19)32977-0","volume":"395","author":"P Cockwell","year":"2020","unstructured":"Cockwell, P. & Fisher, L.-A. The global burden of chronic kidney disease. Lancet 395, 662\u2013664 (2020).","journal-title":"Lancet"},{"key":"1078_CR19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","volume":"15","author":"M Bl\u00fcher","year":"2019","unstructured":"Bl\u00fcher, M. Obesity: global epidemiology and pathogenesis. Nat. Rev. Endocrinol. 15, 288\u2013298 (2019).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1078_CR20","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.2337\/dc06-0138","volume":"29","author":"LO Schulz","year":"2006","unstructured":"Schulz, L. O. et al. Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the U.S. Diabetes Care 29, 1866\u20131871 (2006).","journal-title":"Diabetes Care"},{"key":"1078_CR21","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1017\/S0007114510005076","volume":"105","author":"P Scarborough","year":"2011","unstructured":"Scarborough, P. et al. Increased energy intake entirely accounts for increase in body weight in women but not in men in the UK between 1986 and 2000. Br. J. Nutr. 105, 1399\u20131404 (2011).","journal-title":"Br. J. Nutr."},{"key":"1078_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2891-12-130","volume":"12","author":"TJ Carden","year":"2013","unstructured":"Carden, T. J. & Carr, T. P. Food availability of glucose and fat, but not fructose, increased in the U.S. between 1970 and 2009: analysis of the USDA food availability data system. Nutr. J. 12, 130 (2013).","journal-title":"Nutr. J."},{"key":"1078_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/oby.20963","volume":"23","author":"CA Myers","year":"2015","unstructured":"Myers, C. A., Slack, T., Martin, C. K., Broyles, S. T. & Heymsfield, S. B. Regional disparities in obesity prevalence in the United States: a spatial regime analysis. Obesity 23, 481\u2013487 (2015).","journal-title":"Obesity"},{"key":"1078_CR24","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41574-018-0026-0","volume":"14","author":"A Peeters","year":"2018","unstructured":"Peeters, A. Obesity and the future of food policies that promote healthy diets. Nat. Rev. Endocrinol. 14, 430\u2013437 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1078_CR25","doi-asserted-by":"publisher","first-page":"e2419029","DOI":"10.1001\/jamanetworkopen.2024.19029","volume":"7","author":"G Chodick","year":"2024","unstructured":"Chodick, G. et al. Heritability of body mass index among familial generations. JAMA Netw. Open 7, e2419029\u2013e2419029 (2024).","journal-title":"JAMA Netw. Open"},{"key":"1078_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004629","volume":"22","author":"M-K Tsai","year":"2025","unstructured":"Tsai, M.-K. et al. Cardiovascular\u2013kidney\u2013metabolic syndrome and all-cause and cardiovascular mortality: a retrospective cohort study. PLOS Med. 22, e1004629 (2025).","journal-title":"PLOS Med."},{"key":"1078_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101843","volume":"4","author":"Y Chen","year":"2025","unstructured":"Chen, Y. et al. Prevalence and mortality association of different stages of cardiovascular-kidney-metabolic syndrome. JACC Adv. 4, 101843 (2025).","journal-title":"JACC Adv."},{"key":"1078_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.118585","volume":"397","author":"N Li","year":"2024","unstructured":"Li, N. et al. Association between different stages of cardiovascular-kidney-metabolic syndrome and the risk of all-cause mortality. Atherosclerosis 397, 118585 (2024).","journal-title":"Atherosclerosis"},{"key":"1078_CR29","doi-asserted-by":"publisher","first-page":"e2435783","DOI":"10.1001\/jamanetworkopen.2024.35783","volume":"7","author":"PR Vieira de Oliveira Salerno","year":"2024","unstructured":"Vieira de Oliveira Salerno, P. R. et al. Social and environmental determinants of health and cardio-kidney-metabolic syndrome \u2013 related mortality. JAMA Netw. Open 7, e2435783\u2013e2435783 (2024).","journal-title":"JAMA Netw. Open"},{"key":"1078_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12986-025-00974-5","volume":"22","author":"L Duan","year":"2025","unstructured":"Duan, L. et al. Dietary antioxidants and mortality in early-stage CKM syndrome: insights from NHANES. Nutr. Metab. 22, 77 (2025).","journal-title":"Nutr. Metab."},{"key":"1078_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14113888","volume":"14","author":"BS Kim","year":"2025","unstructured":"Kim, B. S. et al. Longitudinal changes in cardiovascular-kidney-metabolic syndrome stages and their impact on outcomes: a nationwide cohort study. J. Clin. Med. 14, 3888 (2025).","journal-title":"J. Clin. Med."},{"key":"1078_CR32","doi-asserted-by":"publisher","first-page":"711S","DOI":"10.1093\/ajcn\/57.5.711S","volume":"57","author":"RPE Mensink","year":"1993","unstructured":"Mensink, R. P.E Effects of saturated fatty acids on serum lipids and lipoproteins: a systematic review and regression analysis. Am. J. Clin. Nutr. 57, 711S\u2013714S (1993).","journal-title":"Am. J. Clin. Nutr."},{"key":"1078_CR33","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1161\/CIR.0000000000001171","volume":"148","author":"A Agarwala","year":"2023","unstructured":"Agarwala, A. et al. Implementation of prevention science to eliminate health care inequities in achieving cardiovascular health: a scientific statement from the American Heart Association. Circulation 148, 1183\u20131193 (2023).","journal-title":"Circulation"},{"key":"1078_CR34","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1093\/ndt\/gfac224","volume":"38","author":"S Sawhney","year":"2023","unstructured":"Sawhney, S. et al. Care processes and outcomes of deprivation across the clinical course of kidney disease: findings from a high-income country with universal healthcare. Nephrol. Dial. Transpl. 38, 1170\u20131182 (2023).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1078_CR35","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1046\/j.1523-1755.2000.00284.x","volume":"58","author":"J-M Halimi","year":"2000","unstructured":"Halimi, J.-M. et al. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int. 58, 1285\u20131292 (2000).","journal-title":"Kidney Int."},{"key":"1078_CR36","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1161\/01.ATV.0000199268.27395.4f","volume":"26","author":"TS Perlstein","year":"2006","unstructured":"Perlstein, T. S. & Lee, R. T. Smoking, metalloproteinases, and vascular disease. Arterioscler. Thromb. Vasc. Biol. 26, 250\u2013256 (2006).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1078_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002637","volume":"8","author":"S Vattikuti","year":"2012","unstructured":"Vattikuti, S., Guo, J. & Chow, C. C. Heritability and genetic correlations explained by common SNPs for metabolic syndrome traits. PLoS Genet. 8, e1002637 (2012).","journal-title":"PLoS Genet."},{"key":"1078_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-02017-w","volume":"22","author":"RD Triatin","year":"2023","unstructured":"Triatin, R. D. et al. Familial co-aggregation and shared genetics of cardiometabolic disorders and traits: data from the multi-generational Lifelines Cohort Study. Cardiovasc. Diabetol. 22, 282 (2023).","journal-title":"Cardiovasc. Diabetol."},{"key":"1078_CR39","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1053\/j.ajkd.2020.11.012","volume":"77","author":"J Zhang","year":"2021","unstructured":"Zhang, J., Thio, C. H. L., Gansevoort, R. T. & Snieder, H. Familial aggregation of CKD and heritability of kidney biomarkers in the general population: the Lifelines Cohort Study. Am. J. Kidney Dis. 77, 869\u2013878 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"1078_CR40","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/s41588-022-01233-6","volume":"54","author":"KG Aragam","year":"2022","unstructured":"Aragam, K. G. et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. Nat. Genet. 54, 1803\u20131815 (2022).","journal-title":"Nat. Genet."},{"key":"1078_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24491-0","volume":"12","author":"KJ Stanzick","year":"2021","unstructured":"Stanzick, K. J. et al. Discovery and prioritization of variants and genes for kidney function in >1.2 million individuals. Nat. Commun. 12, 4350 (2021).","journal-title":"Nat. Commun."},{"key":"1078_CR42","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41588-022-01058-3","volume":"54","author":"A Mahajan","year":"2022","unstructured":"Mahajan, A. et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nat. Genet. 54, 560\u2013572 (2022).","journal-title":"Nat. Genet."},{"key":"1078_CR43","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf8683","volume":"373","author":"P Akbari","year":"2021","unstructured":"Akbari, P. et al. Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity. Science 373, eabf8683 (2021).","journal-title":"Science"},{"key":"1078_CR44","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1038\/s41591-024-03284-0","volume":"30","author":"O Jamialahmadi","year":"2024","unstructured":"Jamialahmadi, O. et al. Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease. Nat. Med. 30, 3614\u20133623 (2024).","journal-title":"Nat. Med."},{"key":"1078_CR45","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.2215\/CJN.11971018","volume":"14","author":"X Chen","year":"2019","unstructured":"Chen, X., Bhuiyan, I., Kuja-Halkola, R., Magnusson, P. K. E. & Svensson, P. Genetic and environmental influences on the correlations between traits of metabolic syndrome and CKD. Clin. J. Am. Soc. Nephrol. 14, 1590\u20131596 (2019).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1078_CR46","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/ije\/dyab203","volume":"50","author":"J Zheng","year":"2022","unstructured":"Zheng, J. et al. Trans-ethnic Mendelian-randomization study reveals causal relationships between cardiometabolic factors and chronic kidney disease. Int. J. Epidemiol. 50, 1995\u20132010 (2022).","journal-title":"Int. J. Epidemiol."},{"key":"1078_CR47","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1038\/s41591-025-03872-8","volume":"31","author":"D Hirohama","year":"2025","unstructured":"Hirohama, D. et al. The proteogenomic landscape of the human kidney and implications for cardio-kidney-metabolic health. Nat. Med. 31, 3917\u20133929 (2025).","journal-title":"Nat. Med."},{"key":"1078_CR48","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41431-023-01517-3","volume":"32","author":"C-C Topriceanu","year":"2024","unstructured":"Topriceanu, C.-C., Chaturvedi, N., Mathur, R. & Garfield, V. Validity of European-centric cardiometabolic polygenic scores in multi-ancestry populations. Eur. J. Hum. Genet. 32, 697\u2013707 (2024).","journal-title":"Eur. J. Hum. Genet."},{"key":"1078_CR49","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00439-010-0861-0","volume":"128","author":"S Tzur","year":"2010","unstructured":"Tzur, S. et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum. Genet. 128, 345\u2013350 (2010).","journal-title":"Hum. Genet."},{"key":"1078_CR50","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1193032","volume":"329","author":"G Genovese","year":"2010","unstructured":"Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329, 841\u2013845 (2010).","journal-title":"Science"},{"key":"1078_CR51","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1681\/ASN.2019030240","volume":"30","author":"ME Grams","year":"2019","unstructured":"Grams, M. E. et al. APOL1 kidney risk variants and cardiovascular disease: an individual participant data meta-analysis. J. Am. Soc. Nephrol. 30, 2027\u20132036 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1078_CR52","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1161\/CIRCULATIONAHA.118.036589","volume":"140","author":"AG Bick","year":"2019","unstructured":"Bick, A. G. et al. Association of APOL1 risk alleles with cardiovascular disease in Blacks in the Million Veteran Program. Circulation 140, 1031\u20131040 (2019).","journal-title":"Circulation"},{"key":"1078_CR53","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1056\/NEJMoa2202396","volume":"388","author":"O Egbuna","year":"2023","unstructured":"Egbuna, O. et al. Inaxaplin for proteinuric kidney disease in persons with Two APOL1 Variants. N. Engl. J. Med. 388, 969\u2013979 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR54","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1056\/NEJMoa1605086","volume":"375","author":"AV Khera","year":"2016","unstructured":"Khera, A. V. et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N. Engl. J. Med. 375, 2349\u20132358 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR55","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/S0140-6736(19)30041-8","volume":"393","author":"A Afshin","year":"2019","unstructured":"Afshin, A. et al. Health effects of dietary risks in 195 countries, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 393, 1958\u20131972 (2019).","journal-title":"Lancet"},{"key":"1078_CR56","first-page":"e245","volume":"152","author":"MK Vadiveloo","year":"2025","unstructured":"Vadiveloo, M. K. et al. Ultraprocessed foods and their association with cardiometabolic health: evidence, gaps, and opportunities: a science advisory from the American Heart Association. Circulation 152, e245\u2013e263 (2025).","journal-title":"Circulation"},{"key":"1078_CR57","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1017\/S1368980021003256","volume":"25","author":"C Romero Ferreiro","year":"2022","unstructured":"Romero Ferreiro, C., Mart\u00edn-Arriscado Arroba, C., Cancelas Navia, P., Lora Pablos, D. & G\u00f3mez de la C\u00e1mara, A. Ultra-processed food intake and all-cause mortality: DRECE cohort study. Public Health Nutr. 25, 1854\u20131863 (2022).","journal-title":"Public Health Nutr."},{"key":"1078_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-077310","volume":"384","author":"MM Lane","year":"2024","unstructured":"Lane, M. M. et al. Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses. BMJ 384, e077310 (2024).","journal-title":"BMJ"},{"key":"1078_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/nu17091560","volume":"17","author":"KE Leonberg","year":"2025","unstructured":"Leonberg, K. E., Maski, M. R., Scott, T. M. & Naumova, E. N. Ultra-processed food and chronic kidney disease risk: a systematic review, meta-analysis, and recommendations. Nutrients 17, 1560 (2025).","journal-title":"Nutrients"},{"key":"1078_CR60","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/ejcn.2017.58","volume":"72","author":"M Dinu","year":"2018","unstructured":"Dinu, M., Pagliai, G., Casini, A. & Sofi, F. Mediterranean diet and multiple health outcomes: an umbrella review of meta-analyses of observational studies and randomised trials. Eur. J. Clin. Nutr. 72, 30\u201343 (2018).","journal-title":"Eur. J. Clin. Nutr."},{"key":"1078_CR61","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJM199704173361601","volume":"336","author":"LJ Appel","year":"1997","unstructured":"Appel, L. J. et al. A clinical trial of the effects of dietary patterns on blood pressure. N. Engl. J. Med. 336, 1117\u20131124 (1997).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR62","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1016\/j.jacc.2017.10.011","volume":"70","author":"SP Juraschek","year":"2017","unstructured":"Juraschek, S. P., Miller, E. R. 3rd, Weaver, C. M. & Appel, L. J. Effects of sodium reduction and the DASH diet in relation to baseline blood pressure. J. Am. Coll. Cardiol. 70, 2841\u20132848 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1078_CR63","doi-asserted-by":"publisher","first-page":"e2325658","DOI":"10.1001\/jamanetworkopen.2023.25658","volume":"6","author":"T Wang","year":"2023","unstructured":"Wang, T. et al. Vegetarian dietary patterns and cardiometabolic risk in people with or at high risk of cardiovascular disease: a systematic review and meta-analysis. JAMA Netw. Open 6, e2325658\u2013e2325658 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1078_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003371","volume":"17","author":"H Kim","year":"2020","unstructured":"Kim, H., Lee, K., Rebholz, C. M. & Kim, J. Plant-based diets and incident metabolic syndrome: results from a South Korean prospective cohort study. PLoS Med. 17, e1003371 (2020).","journal-title":"PLoS Med."},{"key":"1078_CR65","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.034996","volume":"13","author":"J Li","year":"2024","unstructured":"Li, J. et al. Social risk profile and cardiovascular-kidney-metabolic syndrome in US adults. J. Am. Heart Assoc. 13, e034996 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"1078_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101830","volume":"4","author":"R Ibrahim","year":"2025","unstructured":"Ibrahim, R. et al. Historical redlining and cardio-kidney-metabolic disease risk factors, prevalence, and outcomes. JACC Adv. 4, 101830 (2025).","journal-title":"JACC Adv."},{"key":"1078_CR67","first-page":"1124","volume":"31","author":"SW Tobe","year":"2015","unstructured":"Tobe, S. W., Maar, M., Roy, M. A. & Warburton, D. E. Preventing cardiovascular and renal disease in Canada\u2019s aboriginal populations. Can. J. Cardiol. 31, 1124\u20131129 (2015).","journal-title":"Can. J. Cardiol."},{"key":"1078_CR68","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ijcard.2013.12.026","volume":"171","author":"A Brown","year":"2014","unstructured":"Brown, A. et al. Cardiometabolic risk and disease in Indigenous Australians: the Heart of the Heart study. Int. J. Cardiol. 171, 377\u2013383 (2014).","journal-title":"Int. J. Cardiol."},{"key":"1078_CR69","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0140-6736(09)60914-4","volume":"374","author":"M Gracey","year":"2009","unstructured":"Gracey, M. & King, M. Indigenous health part 1: determinants and disease patterns. Lancet 374, 65\u201375 (2009).","journal-title":"Lancet"},{"key":"1078_CR70","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41581-025-01016-2","volume":"22","author":"S Tungsanga","year":"2026","unstructured":"Tungsanga, S. et al. Global landscape of kidney health across Indigenous populations. Nat. Rev. Nephrol. 22, 99\u2013121 (2026).","journal-title":"Nat. Rev. Nephrol."},{"key":"1078_CR71","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1126\/science.adg9931","volume":"381","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Air quality policy should quantify effects on disparities. Science 381, 272\u2013274 (2023).","journal-title":"Science"},{"key":"1078_CR72","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2213-8587(23)00361-3","volume":"12","author":"S Rajagopalan","year":"2024","unstructured":"Rajagopalan, S. et al. Air pollution exposure and cardiometabolic risk. Lancet Diabetes Endocrinol. 12, 196\u2013208 (2024).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1078_CR73","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2215\/CJN.08350719","volume":"15","author":"MF Blum","year":"2020","unstructured":"Blum, M. F. et al. Particulate matter and albuminuria, glomerular filtration rate, and incident CKD. Clin. J. Am. Soc. Nephrol. 15, 311\u2013319 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1078_CR74","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1001\/jamacardio.2022.3729","volume":"7","author":"EJ Brandt","year":"2022","unstructured":"Brandt, E. J., Chang, T., Leung, C., Ayanian, J. Z. & Nallamothu, B. K. Food insecurity among individuals with cardiovascular disease and cardiometabolic risk factors across race and ethnicity in 1999\u20132018. JAMA Cardiol. 7, 1218\u20131226 (2022).","journal-title":"JAMA Cardiol."},{"key":"1078_CR75","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev-publhealth-040218-043657","volume":"41","author":"JF Sallis","year":"2020","unstructured":"Sallis, J. F. et al. Built environment, physical activity, and obesity: findings from the International Physical Activity and Environment Network (IPEN) Adult Study. Annu. Rev. Public. Health 41, 119\u2013139 (2020).","journal-title":"Annu. Rev. Public. Health"},{"key":"1078_CR76","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.123.067461","volume":"149","author":"S Rajagopalan","year":"2024","unstructured":"Rajagopalan, S. et al. The urban environment and cardiometabolic health. Circulation 149, 1298\u20131314 (2024).","journal-title":"Circulation"},{"key":"1078_CR77","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.amepre.2021.03.014","volume":"61","author":"SE Conderino","year":"2021","unstructured":"Conderino, S. E., Feldman, J. M., Spoer, B., Gourevitch, M. N. & Thorpe, L. E. Social and economic differences in neighborhood walkability across 500 U.S. cities. Am. J. Prev. Med. 61, 394\u2013401 (2021).","journal-title":"Am. J. Prev. Med."},{"key":"1078_CR78","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2023-012646","volume":"8","author":"S Han","year":"2023","unstructured":"Han, S., Su, B., Zhao, Y., Chen, C. & Zheng, X. Widening rural-urban gap in life expectancy in China since COVID-19. BMJ Glob. Health 8, e012646 (2023).","journal-title":"BMJ Glob. Health"},{"key":"1078_CR79","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1001\/jamacardio.2025.0538","volume":"10","author":"M Liu","year":"2025","unstructured":"Liu, M., Marinacci, L. X., Joynt Maddox, K. E. & Wadhera, R. K. Cardiovascular health among rural and urban US adults \u2014 healthcare, lifestyle, and social factors. JAMA Cardiol. 10, 585\u2013594 (2025).","journal-title":"JAMA Cardiol."},{"key":"1078_CR80","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1093\/eurheartj\/ehac249","volume":"43","author":"P Joseph","year":"2022","unstructured":"Joseph, P. et al. Cardiovascular disease, mortality, and their associations with modifiable risk factors in a multi-national South Asia cohort: a PURE substudy. Eur. Heart J. 43, 2831\u20132840 (2022).","journal-title":"Eur. Heart J."},{"key":"1078_CR81","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1093\/ije\/dyaa226","volume":"50","author":"T Adair","year":"2020","unstructured":"Adair, T. & Lopez, A. D. An egalitarian society? Widening inequalities in premature mortality from non-communicable diseases in Australia, 2006\u201316. Int. J. Epidemiol. 50, 783\u2013796 (2020).","journal-title":"Int. J. Epidemiol."},{"key":"1078_CR82","doi-asserted-by":"publisher","first-page":"j5855","DOI":"10.1136\/bmj.j5855","volume":"360","author":"A Hackshaw","year":"2018","unstructured":"Hackshaw, A., Morris, J. K., Boniface, S., Tang, J. L. & Milenkovi\u0107, D. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ 360, j5855 (2018).","journal-title":"BMJ"},{"key":"1078_CR83","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/ndt\/gfw452","volume":"32","author":"J Xia","year":"2017","unstructured":"Xia, J. et al. Cigarette smoking and chronic kidney disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Nephrol. Dial. Transpl. 32, 475\u2013487 (2017).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1078_CR84","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S2213-8587(15)00316-2","volume":"3","author":"A Pan","year":"2015","unstructured":"Pan, A., Wang, Y., Talaei, M., Hu, F. B. & Wu, T. Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 3, 958\u2013967 (2015).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1078_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2025.118885","volume":"303","author":"Y He","year":"2025","unstructured":"He, Y. et al. Cadmium exposure and advanced cardiovascular-kidney-metabolic syndrome: an integrated multi-organ perspective based on epidemiology and adverse outcome pathways. Ecotoxicol. Environ. Saf. 303, 118885 (2025).","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"1078_CR86","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1056\/NEJMra2030281","volume":"385","author":"S Rajagopalan","year":"2021","unstructured":"Rajagopalan, S. & Landrigan, P. J. Pollution and the Heart. N. Engl. J. Med. 385, 1881\u20131892 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR87","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000046298","volume":"104","author":"J Wei","year":"2025","unstructured":"Wei, J., Hu, X. & Li, Y. Heavy metals and mortality in cardiovascular-kidney-metabolic syndrome: insights from the NHANES cohort. Medicine 104, e46298 (2025).","journal-title":"Medicine"},{"key":"1078_CR88","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3310","volume":"362","author":"R Chowdhury","year":"2018","unstructured":"Chowdhury, R. et al. Environmental toxic metal contaminants and risk of cardiovascular disease: systematic review and meta-analysis. BMJ 362, k3310 (2018).","journal-title":"BMJ"},{"key":"1078_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0315688","volume":"19","author":"P-F Kuo","year":"2024","unstructured":"Kuo, P.-F., Huang, Y.-T., Chuang, M.-H. & Jiang, M.-Y. Association of low-level heavy metal exposure with risk of chronic kidney disease and long-term mortality. PLoS ONE 19, e0315688 (2024).","journal-title":"PLoS ONE"},{"key":"1078_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-31637-3","volume":"16","author":"Q Wu","year":"2026","unstructured":"Wu, Q. et al. Associations of metal mixtures with insulin resistance and glucose homeostasis in U.S. adults from the NHANES 2011\u20132018. Sci. Rep. 16, 2047 (2026).","journal-title":"Sci. Rep."},{"key":"1078_CR91","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13510","volume":"23","author":"J Wu","year":"2022","unstructured":"Wu, J. et al. Sedentary time and the risk of metabolic syndrome: a systematic review and dose-response meta-analysis. Obes. Rev. 23, e13510 (2022).","journal-title":"Obes. Rev."},{"key":"1078_CR92","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2188\/jea.JE20210155","volume":"33","author":"M Hara","year":"2023","unstructured":"Hara, M. et al. Moderate-to-vigorous physical activity and sedentary behavior are independently associated with renal function: a cross-sectional study. J. Epidemiol. 33, 285\u2013293 (2023).","journal-title":"J. Epidemiol."},{"key":"1078_CR93","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(12)61031-9","volume":"380","author":"IM Lee","year":"2012","unstructured":"Lee, I. M. et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 380, 219\u2013229 (2012).","journal-title":"Lancet"},{"key":"1078_CR94","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamacardio.2016.1567","volume":"1","author":"A Pandey","year":"2016","unstructured":"Pandey, A. et al. Continuous dose-response association between sedentary time and risk for cardiovascular disease: a meta-analysis. JAMA Cardiol. 1, 575\u2013583 (2016).","journal-title":"JAMA Cardiol."},{"key":"1078_CR95","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jacc.2024.10.065","volume":"85","author":"E Ajufo","year":"2025","unstructured":"Ajufo, E. et al. Accelerometer-measured sedentary behavior and risk of future cardiovascular disease. J. Am. Coll. Cardiol. 85, 473\u2013486 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1078_CR96","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1001\/jamacardio.2024.1321","volume":"9","author":"DS Kazi","year":"2024","unstructured":"Kazi, D. S. et al. Climate change and cardiovascular health: a systematic review. JAMA Cardiol. 9, 748\u2013757 (2024).","journal-title":"JAMA Cardiol."},{"key":"1078_CR97","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1681\/ASN.2021111520","volume":"33","author":"MF Blum","year":"2022","unstructured":"Blum, M. F. et al. Hurricanes and mortality among patients receiving dialysis. J. Am. Soc. Nephrol. 33, 1757\u20131766 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1078_CR98","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1053\/j.ajkd.2024.04.010","volume":"84","author":"MF Blum","year":"2024","unstructured":"Blum, M. F. et al. Extreme humid-heat exposure and mortality among patients receiving dialysis. Am. J. Kidney Dis. 84, 582\u2013592.e1 (2024).","journal-title":"Am. J. Kidney Dis."},{"key":"1078_CR99","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.038251","volume":"14","author":"PR Vieira de Oliveira Salerno","year":"2025","unstructured":"Vieira de Oliveira Salerno, P. R. et al. Climate vulnerability and cardiovascular-kidney-metabolic disease in the United States. J. Am. Heart Assoc. 14, e038251 (2025).","journal-title":"J. Am. Heart Assoc."},{"key":"1078_CR100","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41581-025-00971-0","volume":"21","author":"Y-H Lee","year":"2025","unstructured":"Lee, Y.-H., Zheng, C.-M., Wang, Y.-J., Wang, Y.-L. & Chiu, H.-W. Effects of microplastics and nanoplastics on the kidney and cardiovascular system. Nat. Rev. Nephrol. 21, 585\u2013596 (2025).","journal-title":"Nat. Rev. Nephrol."},{"key":"1078_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.envpol.2025.126319","volume":"375","author":"VC Shruti","year":"2025","unstructured":"Shruti, V. C., Kutralam-Muniasamy, G., P\u00e9rez-Guevara, F. & Alvarez, R. C. Exploring the micro- and nanoplastics-diabetes nexus: shattered barriers, toxic links, and methodological horizons. Env. Pollut. 375, 126319 (2025).","journal-title":"Env. Pollut."},{"key":"1078_CR102","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1056\/NEJMoa2309822","volume":"390","author":"R Marfella","year":"2024","unstructured":"Marfella, R. et al. Microplastics and nanoplastics in atheromas and cardiovascular events. N. Engl. J. Med. 390, 900\u2013910 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR103","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1161\/CIR.0000000000001160","volume":"148","author":"JJ Rose","year":"2023","unstructured":"Rose, J. J. et al. Cardiopulmonary impact of electronic cigarettes and vaping products: a scientific statement from the American Heart Association. Circulation 148, 703\u2013728 (2023).","journal-title":"Circulation"},{"key":"1078_CR104","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13269","volume":"22","author":"F Battista","year":"2021","unstructured":"Battista, F. et al. Effect of exercise on cardiometabolic health of adults with overweight or obesity: focus on blood pressure, insulin resistance, and intrahepatic fat \u2014 a systematic review and meta-analysis. Obes. Rev. 22, e13269 (2021).","journal-title":"Obes. Rev."},{"key":"1078_CR105","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002014","volume":"4","author":"X Lin","year":"2015","unstructured":"Lin, X. et al. Effects of exercise training on cardiorespiratory fitness and biomarkers of cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials. J. Am. Heart Assoc. 4, e002014 (2015).","journal-title":"J. Am. Heart Assoc."},{"key":"1078_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18052635","volume":"18","author":"HS Lee","year":"2021","unstructured":"Lee, H. S. & Lee, J. Effects of exercise interventions on weight, body mass index, lean body mass and accumulated visceral fat in overweight and obese individuals: a systematic review and meta-analysis of randomized controlled trials. Int. J. Environ. Res. Public. Health 18, 2635 (2021).","journal-title":"Int. J. Environ. Res. Public. Health"},{"key":"1078_CR107","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1681\/ASN.0000000636","volume":"36","author":"SI Hallan","year":"2025","unstructured":"Hallan, S. I. et al. Long-term physical exercise for preventing CKD in older adults: a randomized clinical trial. J. Am. Soc. Nephrol. 36, 1352\u20131362 (2025).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1078_CR108","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1161\/CIRCRESAHA.124.325533","volume":"137","author":"LA Mounsey","year":"2025","unstructured":"Mounsey, L. A., Guo, M., Lau, E. S. & Ho, J. E. Exercise training in heart failure: clinical benefits and mechanisms. Circ. Res. 137, 273\u2013289 (2025).","journal-title":"Circ. Res."},{"key":"1078_CR109","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nrneph.2013.145","volume":"9","author":"W Fenske","year":"2013","unstructured":"Fenske, W. et al. Obesity-related cardiorenal disease: the benefits of bariatric surgery. Nat. Rev. Nephrol. 9, 539\u2013551 (2013).","journal-title":"Nat. Rev. Nephrol."},{"key":"1078_CR110","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa1700459","volume":"377","author":"TD Adams","year":"2017","unstructured":"Adams, T. D. et al. Weight and metabolic outcomes 12 years after gastric bypass. N. Engl. J. Med. 377, 1143\u20131155 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR111","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41581-020-0323-4","volume":"16","author":"NG Docherty","year":"2020","unstructured":"Docherty, N. G. & le Roux, C. W. Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus. Nat. Rev. Nephrol. 16, 709\u2013720 (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"1078_CR112","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/SLA.0000000000003554","volume":"271","author":"GM Campos","year":"2020","unstructured":"Campos, G. M. et al. Changes in utilization of bariatric surgery in the United States From 1993 to 2016. Ann. Surg. 271, 201\u2013209 (2020).","journal-title":"Ann. Surg."},{"key":"1078_CR113","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1007\/s11695-009-0054-x","volume":"20","author":"AE Wallace","year":"2010","unstructured":"Wallace, A. E., Young-Xu, Y., Hartley, D. & Weeks, W. B. Racial, socioeconomic, and rural-urban disparities in obesity-related bariatric surgery. Obes. Surg. 20, 1354\u20131360 (2010).","journal-title":"Obes. Surg."},{"key":"1078_CR114","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s11695-018-3539-7","volume":"29","author":"M Ohta","year":"2019","unstructured":"Ohta, M. et al. Bariatric\/metabolic surgery in the Asia-Pacific region: APMBSS 2018 Survey. Obes. Surg. 29, 534\u2013541 (2019).","journal-title":"Obes. Surg."},{"key":"1078_CR115","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1007\/s11695-014-1537-y","volume":"25","author":"O Borisenko","year":"2015","unstructured":"Borisenko, O. et al. Clinical indications, utilization, and funding of bariatric surgery in Europe. Obes. Surg. 25, 1408\u20131416 (2015).","journal-title":"Obes. Surg."},{"key":"1078_CR116","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000001221","volume":"150","author":"D Laddu","year":"2024","unstructured":"Laddu, D. et al. Implementation of obesity science into clinical practice: a scientific statement from the American Heart Association. Circulation 150, e7\u2013e19 (2024).","journal-title":"Circulation"},{"key":"1078_CR117","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989\u20131002 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR118","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne, L. J. et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N. Engl. J. Med. 393, 26\u201336 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR119","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834\u20131844 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR120","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221\u20132232 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR121","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","volume":"30","author":"HM Colhoun","year":"2024","unstructured":"Colhoun, H. M. et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat. Med. 30, 2058\u20132066 (2024).","journal-title":"Nat. Med."},{"key":"1078_CR122","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109\u2013121 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR123","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.4182","volume":"2","author":"LA Eberly","year":"2021","unstructured":"Eberly, L. A. et al. Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US. JAMA Health Forum 2, e214182 (2021).","journal-title":"JAMA Health Forum"},{"key":"1078_CR124","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.1111\/dom.16608","volume":"27","author":"H Wallace","year":"2025","unstructured":"Wallace, H. et al. Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: analysis of an Australian primary care dataset. Diabetes Obes. Metab. 27, 5599\u20135611 (2025).","journal-title":"Diabetes Obes. Metab."},{"key":"1078_CR125","first-page":"e228","volume":"31","author":"M Ukhanova","year":"2025","unstructured":"Ukhanova, M. Trends in glucagon-like peptide 1 receptor agonist prescribing patterns. Am. J. Manag. Care 31, e228\u2013e234 (2025).","journal-title":"Am. J. Manag. Care"},{"key":"1078_CR126","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/DMSO.S141235","volume":"10","author":"MV, Sikirica","year":"2017","unstructured":"Sikirica, M. V. et al. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab. Syndr. Obes. 10, 403\u2013412 (2017).","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"1078_CR127","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.037456","volume":"13","author":"LA Mavromatis","year":"2024","unstructured":"Mavromatis, L. A. et al. PREVENT risk score and use of cardioprotective agents in type 2 diabetes: an analysis of NHANES 2013 to 2020. J. Am. Heart Assoc. 13, e037456 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"1078_CR128","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117\u20132128 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR129","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295\u20132306 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR130","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644\u2013657 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR131","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413\u20131424 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR132","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451\u20131461 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR133","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJ Heerspink","year":"2020","unstructured":"Heerspink, H. J. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436\u20131446 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR134","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink, H. J., Perkins, B. A., Fitchett, D. H., Husain, M. & Cherney, D. Z. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134, 752\u2013772 (2016).","journal-title":"Circulation"},{"key":"1078_CR135","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jacc.2024.05.057","volume":"84","author":"JI Shin","year":"2024","unstructured":"Shin, J. I. et al. Prescription patterns for sodium-glucose cotransporter 2 inhibitors in U.S. health systems. J. Am. Coll. Cardiol. 84, 683\u2013693 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1078_CR136","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1001\/jamacardio.2025.2145","volume":"10","author":"A El Rafei","year":"2025","unstructured":"El Rafei, A. et al. Sodium-glucose cotransporter 2 inhibitor use for heart failure in US ambulatory cardiovascular care. JAMA Cardiol. 10, 904\u2013913 (2025).","journal-title":"JAMA Cardiol."},{"key":"1078_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112242","volume":"224","author":"J Lin","year":"2025","unstructured":"Lin, J. et al. Trends in use of sodium-glucose cotransporter 2 inhibitors among people with type 2 diabetes following hospitalisation with heart failure: a population-based study. Diabetes Res. Clin. Pract. 224, 112242 (2025).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1078_CR138","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pcd.2024.10.007","volume":"19","author":"W Raat","year":"2025","unstructured":"Raat, W., Mamouris, P., Mathieu, C., Goderis, G. & Vaes, B. Trends in type 2 diabetes medication use and guideline adherence in Belgian primary care (2019\u20132023). Prim. Care Diabetes 19, 29\u201334 (2025).","journal-title":"Prim. Care Diabetes"},{"key":"1078_CR139","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-025-04171-7","volume":"26","author":"TG Jenssen","year":"2025","unstructured":"Jenssen, T. G., Bodeg\u00e5rd, J., Sveen, K. A., Thuresson, M. & Birkeland, K. I. Prevalence, outcomes, costs, and treatments of a contemporary population with chronic kidney disease in Norway: a nationwide observational study. BMC Nephrol. 26, 393 (2025).","journal-title":"BMC Nephrol."},{"key":"1078_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102426","volume":"68","author":"AK Forbes","year":"2024","unstructured":"Forbes, A. K. et al. Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study. EClinicalMedicine 68, 102426 (2024).","journal-title":"EClinicalMedicine"},{"key":"1078_CR141","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2018.3024","volume":"319","author":"SL Zheng","year":"2018","unstructured":"Zheng, S. L. et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA 319, 1580\u20131591 (2018).","journal-title":"JAMA"},{"key":"1078_CR142","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219\u20132229 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR143","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt, B. et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 385, 2252\u20132263 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR144","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon, S. D. et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 391, 1475\u20131485 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR145","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1161\/CIRCULATIONAHA.124.072055","volume":"151","author":"M Vaduganathan","year":"2025","unstructured":"Vaduganathan, M. et al. Effects of the nonsteroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure. Circulation 151, 149\u2013158 (2025).","journal-title":"Circulation"},{"key":"1078_CR146","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1053\/j.ajkd.2024.08.003","volume":"85","author":"SD Navaneethan","year":"2025","unstructured":"Navaneethan, S. D. et al. KDOQI US commentary on the KDIGO 2024 clinical practice guideline for the evaluation and management of CKD. Am. J. Kidney Dis. 85, 135\u2013176 (2025).","journal-title":"Am. J. Kidney Dis."},{"key":"1078_CR147","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray, K. K. et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N. Engl. J. Med. 382, 1507\u20131519 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR148","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru, K. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429\u2013434 (2021).","journal-title":"Nature"},{"key":"1078_CR149","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","volume":"392","author":"SE Nissen","year":"2025","unstructured":"Nissen, S. E. et al. Lepodisiran \u2014 a long-duration small interfering RNA targeting lipoprotein(a). N. Engl. J. Med. 392, 1673\u20131683 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR150","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","volume":"403","author":"KR Tuttle","year":"2024","unstructured":"Tuttle, K. R. et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet 403, 379\u2013390 (2024).","journal-title":"Lancet"},{"key":"1078_CR151","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2025.9413","volume":"334","author":"M Saxena","year":"2025","unstructured":"Saxena, M. et al. Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the Launch-HTN randomized clinical trial. JAMA 334, 409\u2013418 (2025).","journal-title":"JAMA"},{"key":"1078_CR152","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire, D. K. et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N. Engl. J. Med. 392, 2001\u20132012 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR153","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff, A. M. et al. Triple\u2013hormone-receptor agonist retatrutide for obesity \u2014 a phase 2 trial. N. Engl. J. Med. 389, 514\u2013526 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1078_CR154","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","volume":"402","author":"JP Frias","year":"2023","unstructured":"Frias, J. P. et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet 402, 720\u2013730 (2023).","journal-title":"Lancet"},{"key":"1078_CR155","unstructured":"Levin, A. et al. The kidney in the middle: KDIGO guidelines address multiple key components of cardiovascular-kidney-metabolic syndrome. Kidney Syndr. (in the press)."},{"key":"1078_CR156","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","volume":"149","author":"SS Khan","year":"2024","unstructured":"Khan, S. S. et al. Development and validation of the American Heart Association\u2019s PREVENT equations. Circulation 149, 430\u2013449 (2024).","journal-title":"Circulation"},{"key":"1078_CR157","doi-asserted-by":"publisher","first-page":"e2438311","DOI":"10.1001\/jamanetworkopen.2024.38311","volume":"7","author":"B Scheuermann","year":"2024","unstructured":"Scheuermann, B. et al. External validation of the American Heart Association PREVENT cardiovascular disease risk equations. JAMA Netw. Open. 7, e2438311\u2013e2438311 (2024).","journal-title":"JAMA Netw. Open."},{"key":"1078_CR158","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.039454","volume":"14","author":"H Zhou","year":"2025","unstructured":"Zhou, H. et al. Evaluation and comparison of the PREVENT and pooled cohort equations for 10-year atherosclerotic cardiovascular risk prediction. J. Am. Heart Assoc. 14, e039454 (2025).","journal-title":"J. Am. Heart Assoc."},{"key":"1078_CR159","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/eurjpc\/zwad193","volume":"30","author":"B Delabays","year":"2023","unstructured":"Delabays, B. et al. Comparison of the European and US guidelines for lipid-lowering therapy in primary prevention of cardiovascular disease. Eur. J. Prev. Cardiol. 30, 1856\u20131864 (2023).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"1078_CR160","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1161\/HYP.0000000000000257","volume":"82","author":"DW Jones","year":"2025","unstructured":"Jones, D. W. et al. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM\u00a0guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension 82, e212\u2013e316\u00a0(2025).","journal-title":"Hypertension"},{"key":"1078_CR161","doi-asserted-by":"publisher","unstructured":"Writing Committee Members et al. 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation https:\/\/doi.org\/10.1161\/CIR.0000000000001423 (2026).","DOI":"10.1161\/CIR.0000000000001423"},{"key":"1078_CR162","doi-asserted-by":"publisher","first-page":"e240427","DOI":"10.1001\/jamanetworkopen.2024.0427","volume":"7","author":"JMT Colombijn","year":"2024","unstructured":"Colombijn, J. M. T. et al. Representation of patients with chronic kidney disease in clinical trials of cardiovascular disease medications: a systematic review. JAMA Netw. Open 7, e240427\u2013e240427 (2024).","journal-title":"JAMA Netw. Open"},{"key":"1078_CR163","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/jama.2011.451","volume":"305","author":"N Tangri","year":"2011","unstructured":"Tangri, N. et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA 305, 1553\u20131559 (2011).","journal-title":"JAMA"},{"key":"1078_CR164","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-074068","volume":"381","author":"Q Shi","year":"2023","unstructured":"Shi, Q. et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 381, e074068 (2023).","journal-title":"BMJ"},{"key":"1078_CR165","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao, H. et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ 384, e076410 (2024).","journal-title":"BMJ"},{"key":"1078_CR166","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7326\/M20-0864","volume":"173","author":"No author group","year":"2020","unstructured":"No author group Comparative effectiveness of glucose-lowering drugs for type 2 diabetes. Ann. Intern. Med. 173, 278\u2013286 (2020).","journal-title":"Ann. Intern. Med."},{"key":"1078_CR167","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","volume":"404","author":"PS Jhund","year":"2024","unstructured":"Jhund, P. S. et al. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet 404, 1119\u20131131 (2024).","journal-title":"Lancet"},{"key":"1078_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110210","volume":"195","author":"Q Chen","year":"2023","unstructured":"Chen, Q. et al. Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: a systematic review and meta-analysis. Diabetes Res. Clin. Pract. 195, 110210 (2023).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1078_CR169","doi-asserted-by":"publisher","DOI":"10.1002\/clc.70065","volume":"48","author":"M Ahmed","year":"2025","unstructured":"Ahmed, M. et al. Cardiovascular efficacy and safety of finerenone: a meta-analysis of randomized controlled trials. Clin. Cardiol. 48, e70065 (2025).","journal-title":"Clin. Cardiol."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01078-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01078-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01078-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T13:03:45Z","timestamp":1794920625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01078-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":169,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1078"],"URL":"https:\/\/doi.org\/10.1038\/s41581-026-01078-w","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"13 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}